Nektar Therapeutics (NKTR) is back in focus after publishing peer reviewed Phase 2b REZOLVE AD data for rezpegaldesleukin in The Lancet, highlighting efficacy, safety and patient reported outcomes in moderate to severe atopic dermatitis.
The Lancet publication has arrived after a strong run in Nektar Therapeutics' stock, with the share price at US$74.19 and a 90 day share price return of 31.03% and year to date share price return of 70.87%. The 1 year total shareholder return of 84.64% and very large 3 year total shareholder return above 7x suggest momentum has been building even as the 5 year total shareholder return is down 68.99%.
Scan beyond Nektar Therapeutics and this Lancet-backed immunology story by reviewing hand picked 17 high quality undiscovered gems in autoimmune and chronic disease treatments.
After such a sharp re rating on the REZOLVE AD and Lancet news, the real test for Nektar Therapeutics now is simple: Does the current price still leave enough upside potential to justify the clinical and financial risk?
Most Popular Narrative: 48.6% Undervalued
The most followed valuation narrative for Nektar Therapeutics pegs fair value at $144.40, almost double the last close at $74.19. This puts a spotlight on how aggressive the underlying assumptions are.
Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk, which supports earnings predictability and reduces financial leverage concerns.
To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report. Read the complete narrative.
Want to understand why this valuation almost doubles the current Nektar Therapeutics share price? It leans heavily on future margins, revenue scaling and a rich earnings multiple that only works if several big clinical and commercial milestones line up. The full narrative breaks down how those moving parts fit together and which assumptions really carry the model.
Result: Fair Value of $144.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Nektar Therapeutics still face clear risks, including ongoing losses and the heavy dependence on rezpegaldesleukin trial execution and regulatory outcomes.
Find out about the key risks to this Nektar Therapeutics narrative.
Another View on Nektar Therapeutics: Price To Sales Tells a Tougher Story
The analyst narrative suggests Nektar Therapeutics looks undervalued on a fair value of $144.40 versus a $74.19 share price. A simple P/S check tells a different story. The stock trades on a P/S of 46.4x, compared with a US Pharmaceuticals average of 5.4x and a fair ratio of 11.9x. This signals meaningful valuation risk if sentiment cools.
For investors, that gap means a lot of future success is already reflected in today’s price. The question is whether the clinical and commercial milestones ahead will be strong enough to keep justifying such a premium to peers and to that fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and concern around Nektar Therapeutics feels familiar, do not wait on others to decide the story for you. Review the data, weigh the upside against the risks, and then ground your own view in the 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Nektar Therapeutics?
Do not stop your research with Nektar Therapeutics. Use the Simply Wall St Screener to uncover fresh stocks that fit your style before others catch on.
- Target potential mispricings by scanning a 47 high quality undervalued stocks list that filters for quality businesses trading below their assessed worth.
- Strengthen portfolio resilience by focusing on companies with sturdy finances through a list of solid balance sheet and fundamentals (53 results).
- Prioritise stability without giving up opportunity by reviewing 81 resilient stocks with low risk scores that score well on downside protection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com